Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Questions Novo’s Phase 3 Data for Diabetes Drug

By Drug Discovery Trends Editor | May 23, 2016

An FDA advisory panel released a preliminary review questioning results from a Phase 3 trial for Novo Nordisk’s IDegLira, an experimental diabetes treatment. The drug is a combination of Tresiba (insulin degludec), a long-acting form of insulin for patients with type 1 diabetes, and Victoza (liraglutide), which is an injectable medicine for improving blood sugar in type 2 diabetes patients.

Results of a late-stage study indicated this combination was a better diabetes treatment alternative when compared with Victoza or Tresiba alone, according to FierceBiotech. The agency’s assessment determined that this outcome was deliberately biased in favor of IDegLira in an effort to obtain regulatory approval. 

IDegLira is projected to be an important source of revenue for Novo. Its selling point is that it offers diabetics a better way of managing blood sugar without succumbing to certain issues associated with insulin use like hypoglycemia or rare hypersensitivity reactions, which is why analysts pegged peak sales of this drug at an estimated $1 billion.

However, Reuters reported that the agency’s review determined that the benefit of combining both diabetes drugs into IDegLira came at the cost of a flexible dosing schedule as well as potentially exposing patients to the safety risks commonly associated with liraglutide and degludec.

The FDA’s assessment specified it didn’t find any new, undiscovered safety issues, but the advisory board believed this examination made it too difficult to interpret the clinical trial results.

Ultimately, this report was published ahead of a May 24 meeting where the advisory panel will gather to discuss if Novo’s product should get approval. A similar product made by Sanofi will also be under consideration at that time. 


Filed Under: Drug Discovery

 

Related Articles Read More >

FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE